Therapeutic Proteins And Oral Vaccines Market Research Report By Therapeutic Class (Antibodies, Enzymes, Hormones, Growth factors, Polypeptides), By Vaccine Type (Live attenuated, Inactivated, Toxoid, Subunit, Conjugate), By Disease Indication (Cancer, Cardiovascular diseases, Autoimmune diseases, Infectious diseases, Neurological disorders), By Route of Administration (Intravenous, Subcutaneous, Intramuscular, Oral, Topical) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2032

Therapeutic Proteins And Oral Vaccines Market Overview

As per MRFR analysis, the Therapeutic Proteins And Oral Vaccines Market Size was estimated at 173.82 (USD Billion) in 2022. The Therapeutic Proteins And Oral Vaccines Market Industry is expected to grow from 188.82(USD Billion) in 2023 to 397.8 (USD Billion) by 2032. The Therapeutic Proteins And Oral Vaccines Market CAGR (growth rate) is expected to be around 8.63% during the forecast period (2024 - 2032).

Key Therapeutic Proteins And Oral Vaccines Market Trends Highlighted

The rising prevalence of chronic diseases fuels demand for therapeutic proteins and oral vaccines. Advancements in biotechnology, such as genetic engineering and cell culture technologies, enhance the efficacy and production efficiency of these products.Growing government initiatives and funding support research and development in this field, particularly in developing countries. Additionally, increasing healthcare expenditure and the expansion of healthcare coverage contribute to market growth. The shift towards personalized medicine, where therapies are tailored to individual patient needs, drives the development of targeted therapeutic proteins and oral vaccines. Furthermore, partnerships and collaborations between pharmaceutical companies and research institutions accelerate innovation and bring new products to market.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Therapeutic Proteins And Oral Vaccines Market Drivers

Rising Prevalence of Chronic Diseases

One of the key drivers of the Therapeutic Proteins And Oral Vaccines Market Industry is the increasing prevalence of several chronic diseases, such as cancer, cardiovascular diseases and autoimmune disorders. As cases of these conditions have been increasing, an increasing need for new treatment and targeted therapy has grown. Due to the desired efficacy and specificity of therapeutic proteins and oral vaccines for chronic diseases of other therapeutic products, the market for the population is growing.There is a growing need for improved targeted and personalized treatment approaches that therapeutic proteins and oral vaccines can offer. In this respect, as the occurrence of chronic diseases will continue to increase in the future, the demand for therapeutic proteins and oral vaccines is projected to be highly viable.

Technological Advancements and Innovation

The technological advancements in the Therapeutic Proteins And Oral Vaccines Market Industry are causing the evolution of new and more effective treatment options. The application of biotechnological and genetic knowledge has enhanced the development of proteins that are highly specific to their targets, thereby producing highly powerful therapeutic proteins, which include monoclonal antibodies and fusion proteins. The development of these treatments has enabled the fight of previously incurable diseases such as cancer and autoimmune diseases.Besides, the advancement has facilitated the development of vaccines that are oral, innovative and convenient, thereby expanding the market.

Government Initiatives and Support

Government initiatives and support are crucial factors contributing to the growth of the Therapeutic Proteins And Oral Vaccines Market Industry. Countries all over the world have begun to realize the importance of investing in healthcare and research, which can lead to better health conditions for the general public. This support often comes in the form of funding for research and development and tax incentives for the companies that are involved in the industry.Regulating policies and taxation that are put in place by the government for the companies that are involved in these sectors are also considered a part of government initiatives. Moreover, the government can also heavily focus on running public awareness campaigns to educate people regarding the benefits of therapeutic proteins and oral vaccines, hence leading to an increase in demand for these.

Therapeutic Proteins And Oral Vaccines Market Segment Insights

Therapeutic Proteins And Oral Vaccines Market Therapeutic Class Insights

The Therapeutic Proteins And Oral Vaccines Market is segmented into various classes based on therapeutic applications. Some of the key therapeutic classes in the market include antibodies, enzymes, hormones, growth factors and polypeptides. Each class has its unique characteristics and applications, contributing to the overall growth of the Therapeutic Proteins And Oral Vaccines Market. Antibodies accounted for the largest therapeutic Proteins And Oral Vaccines Market share in 2023, and this trend is expected to continue during the forecast period.Antibodies are proteins produced by the immune system to neutralize pathogens and toxins. They play a crucial role in treating various diseases, including cancer, autoimmune disorders and infectious diseases. Enzymes are proteins that catalyze chemical reactions in the body. They are used in various therapeutic applications, such as enzyme replacement therapy for genetic disorders and digestive enzyme supplements. The increasing prevalence of chronic diseases, such as diabetes and cancer, is driving the demand for enzyme-based therapies, contributing to the growth of the Therapeutic Proteins And Oral Vaccines Market.Hormones are proteins that regulate various physiological processes in the body. They are used in hormone replacement therapy for conditions such as menopause, growth hormone deficiency, and thyroid disorders. The growing geriatric population and the increasing incidence of hormone-related disorders are expected to fuel the demand for hormone-based therapeutics, propelling the growth of the Therapeutic Proteins And Oral Vaccines Market. Growth factors are proteins that stimulate cell growth and proliferation. They are used in various therapeutic applications, including wound healing, bone regeneration, and tissue engineering.Advances in biotechnology and regenerative medicine are expected to drive the demand for growth factor-based therapies, contributing to the growth of the Therapeutic Proteins And Oral Vaccines Market. Polypeptides are short chains of amino acids that have various therapeutic applications. They are used in antibiotics, hormones, and other therapeutic agents. The increasing demand for targeted therapies and the development of novel polypeptide-based drugs are expected to drive the growth of the Therapeutic Proteins And Oral Vaccines Market. Overall, the Therapeutic Proteins And Oral Vaccines Market is expected to continue growing at a steady pace, driven by the increasing prevalence of chronic diseases, the development of novel therapeutic modalities, and the growing demand for personalized and targeted therapies.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Therapeutic Proteins And Oral Vaccines Market Vaccine Type Insights

The Therapeutic Proteins And Oral Vaccines Market is segmented into five types of vaccines, namely, live attenuated, inactivated, toxoid, subunit, and conjugate. Among these segments, the subunit vaccines segment is expected to hold the largest market share in 2023 and is projected to grow at a CAGR of 9.1% from 2023 to 2032. Subunit vaccines are composed of purified pieces of a pathogen, such as a protein or polysaccharide. Since they do not contain any live or inactivated virus or bacteria, they are safer than live attenuated or inactivated vaccines and are less likely to cause side effects.The live attenuated vaccines segment is the second largest segment in the Therapeutic Proteins And Oral Vaccines Market and is expected to grow at a CAGR of 8.5% from 2023 to 2032. Live attenuated vaccines are made from a weakened form of the pathogen and offer long-lasting immunity. However, they can also cause side effects, such as fever and rash. The inactivated vaccines segment is the third largest segment in the Therapeutic Proteins And Oral Vaccines Market and is expected to grow at a CAGR of 8.1% from 2023 to 2032. Inactivated vaccines are made from a killed form of the pathogen and are less likely to cause side effects than live attenuated vaccines.However, they may not provide long-lasting immunity. The toxoid vaccines segment is the fourth largest segment in the Therapeutic Proteins And Oral Vaccines Market and is expected to grow at a CAGR of 7.9% from 2023 to 2032. Toxoid vaccines are made from a toxin that has been chemically modified to make it harmless. They are used to prevent diseases such as tetanus and diphtheria. The conjugate vaccines segment is the fifth largest segment in the Therapeutic Proteins And Oral Vaccines Market.

Therapeutic Proteins And Oral Vaccines Market Disease Indication Insights

The Disease Indication segment of the Therapeutic Proteins And Oral Vaccines Market is expected to grow significantly in the coming years. Key drivers of this growth include the increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, autoimmune diseases, infectious diseases and neurological disorders. The Therapeutic Proteins And Oral Vaccines Market for Cancer is expected to reach a valuation of USD 152.3 billion by 2023, growing at a CAGR of 8.4%. The Cardiovascular diseases segment is also expected to witness significant growth, reaching a valuation of USD 72.6 billion by 2024, growing at a CAGR of 7.9%.The Autoimmune diseases segment is expected to reach a valuation of USD 55.4 billion by 2023, growing at a CAGR of 7.6%. The Infectious diseases segment is expected to reach a valuation of USD 48.3 billion by 2023, growing at a CAGR of 7.2%. The Neurological disorders segment is expected to reach a valuation of USD 39.2 billion by 2032, growing at a CAGR of 6.9%.

Therapeutic Proteins And Oral Vaccines Market Route of Administration Insights

The route of administration segment in the Therapeutic Proteins And Oral Vaccines Market is segmented into intravenous, subcutaneous, intramuscular, oral and topical. Intravenous administration is expected to hold the largest market share in 2023 due to the ease of administration and the ability to deliver drugs directly into the bloodstream. Subcutaneous administration is expected to grow at the highest CAGR during the forecast period due to the increasing use of self-injection devices. The oral route of administration is expected to account for a significant share of the market due to the convenience and ease of administration.The topical route of administration is expected to grow at a moderate CAGR during the forecast period due to the increasing use of topical therapies for the treatment of skin diseases.

Therapeutic Proteins And Oral Vaccines Market Regional Insights

The Therapeutic Proteins And Oral Vaccines Market is segmented into North America, Europe, Asia Pacific, South America and the Middle East and Africa. North America is the largest regional segment, accounting for over 40% of the global market in 2023. Europe is the second-largest region, followed by Asia Pacific. The APAC region is expected to grow at the highest CAGR during the forecast period, driven by factors such as rising disposable income, increasing healthcare expenditure, and the growing prevalence of chronic diseases. The South American and MEA regions are also expected to witness significant growth during the forecast period.The growth of the Therapeutic Proteins And Oral Vaccines Market is attributed to factors such as the rising prevalence of chronic diseases, increasing demand for personalized medicine, and technological advancements in the field of biotechnology. The market is also benefiting from government initiatives and support for the development and production of therapeutic proteins and oral vaccines.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Therapeutic Proteins And Oral Vaccines Market Key Players And Competitive Insights

The major players in the Therapeutic Proteins And Oral Vaccines Market industry are taking various measures to maintain their positions and expand their market share. For example, in March 2023, Pfizer Inc. acquired Arena Pharmaceuticals, which is a clinical-stage biopharmaceutical company, in order to bolster its immunology and inflammation research and development. Moreover, in June 2023, Gilead Sciences Inc. reached an agreement with Arcus Biosciences, Inc. to jointly discover, develop and commercialize cancer-related novel immunotherapies. These measures are projected to foster growth in the Therapeutic Proteins And Oral Vaccines Market industry.

One of the leading players in the Therapeutic Proteins And Oral Vaccines Market is Pfizer Inc. The company, which is headquartered in New York City, is a research-based global Biopharmaceutical company. It develops and manufactures vaccines and other medicines. Pfizer boasts a number of promising therapeutic proteins and oral vaccines in its pipeline. For instance, it will soon start mass production of Comirnaty, which is an mRNA type vaccine for COVID-19. Its leading position is supported by Pfizer’s strong R&D capabilities and worldwide presence. The company has formed a range of agreements with biotech companies in order to promote the arrival of new drugs.

Therefore, one of the main competitors is Moderna, Inc., which is a biotechnology company based in Cambridge, Massachusetts. The company focuses on existing mRNA-based therapeutics and vaccines. Its mRNA COVID-19 vaccine Spikevax has been widely used worldwide. Furthermore, it is currently developing other therapeutics for a number of diseases, such as cancer, cardiovascular diseases, rare diseases and others. Based on the innovative technology platform and promising pipeline, Moderna, Inc. is a significant competitor in the Therapeutic Proteins And Oral Vaccines Market.

Key Companies in the Therapeutic Proteins And Oral Vaccines Market Include

• GSK


• AbbVie Biopharmaceuticals


• RocheGenentech


• Pfizer


• Eli Lilly


• Amgen


• Merck Sharp Dohme


• Bayer HealthCaren


• AstraZeneca


• Genentech


• Novartis


• Johnson Johnson


• SanofiAventis


• Biogen

Therapeutic Proteins And Oral Vaccines Market Industry Developments

The Therapeutic Proteins And Oral Vaccines Market is projected to reach USD 397.8 billion by 2032, exhibiting a CAGR of 8.63% during the forecast period (2024-2032). The market growth is attributed to the rising prevalence of chronic diseases, increasing demand for personalized medicine, and technological advancements in protein engineering and vaccine development.

Key recent developments include the approval of novel therapeutic proteins such as Hemlibra and Evrysdi and the ongoing development of mRNA-based oral vaccines for infectious diseases. Major players in the market include AbbVie, Amgen, and Pfizer, who are investing in research and development to expand their product portfolios and address unmet medical needs.

Therapeutic Proteins And Oral Vaccines Market Segmentation Insights

• Therapeutic Proteins And Oral Vaccines Market Therapeutic Class Outlook
  
  
  
  • Antibodies
  
  
  • Enzymes
  
  
  • Hormones
  
  
  • Growth factors
  
  
  • Polypeptides
  
  
  
  

• Therapeutic Proteins And Oral Vaccines Market Vaccine Type Outlook
  
  
  
  • Live attenuated
  
  
  • Inactivated
  
  
  • Toxoid
  
  
  • Subunit
  
  
  • Conjugate
  
  
  
  

• Therapeutic Proteins And Oral Vaccines Market Disease Indication Outlook
  
  
  
  • Cancer
  
  
  • Cardiovascular diseases
  
  
  • Autoimmune diseases
  
  
  • Infectious diseases
  
  
  • Neurological disorders
  
  
  
  

• Therapeutic Proteins And Oral Vaccines Market Route of Administration Outlook
  
  
  
  • Intravenous
  
  
  • Subcutaneous
  
  
  • Intramuscular
  
  
  • Oral
  
  
  • Topical
  
  
  
  

• Therapeutic Proteins And Oral Vaccines Market Regional Outlook
  
  
  
  • North America
  
  
  • Europe
  
  
  • South America
  
  
  • Asia Pacific
  
  
  • Middle East and Africa